TY - JOUR
T1 - Performance of the herpeselect (focus) and kalon enzyme-linked immunosorbent assays for detection of antibodies against herpes simplex virus type 2 by use of monoclonal antibody-blocking enzyme immunoassay and clinicovirological reference standards in Brazil
AU - Nascimento, Maria Claudia
AU - Ferreira, Suzete
AU - Sabino, Ester
AU - Hamilton, Ingrid
AU - Parry, John
AU - Pannuti, Claudio S.
AU - Mayaud, Philippe
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2007/7
Y1 - 2007/7
N2 - A total of 586 serum samples were used to evaluate the performance of type-specific herpes simplex virus type 2 (HSV-2) commercial enzyme-linked immunosorbent assays (ELISAs) by using the monoclonal antibody-blocking enzyme immunoassay (MAb-EIA) and a clinicovirological panel as reference standards. The Kalon and HerpeSelect ELISAs had similar sensitivities (93.5% and 93.8% compared with the results obtained by MAb-EIA, respectively, and 100% for both ELISAs compared with the results obtained with a clinicovirological panel). The Kalon ELISA had a higher specificity (96.5% and 96.8% compared with the results obtained by MAb-EIA and with a clinicovirological panel, respectively) than the HerpeSelect ELISA (86.9% and 94% compared with the results obtained by MAb-EIA and with a clinicovirological panel, respectively). A higher cutoff significantly improved the specificity of the HerpeSelect ELISA.
AB - A total of 586 serum samples were used to evaluate the performance of type-specific herpes simplex virus type 2 (HSV-2) commercial enzyme-linked immunosorbent assays (ELISAs) by using the monoclonal antibody-blocking enzyme immunoassay (MAb-EIA) and a clinicovirological panel as reference standards. The Kalon and HerpeSelect ELISAs had similar sensitivities (93.5% and 93.8% compared with the results obtained by MAb-EIA, respectively, and 100% for both ELISAs compared with the results obtained with a clinicovirological panel). The Kalon ELISA had a higher specificity (96.5% and 96.8% compared with the results obtained by MAb-EIA and with a clinicovirological panel, respectively) than the HerpeSelect ELISA (86.9% and 94% compared with the results obtained by MAb-EIA and with a clinicovirological panel, respectively). A higher cutoff significantly improved the specificity of the HerpeSelect ELISA.
UR - http://www.scopus.com/inward/record.url?scp=34547637010&partnerID=8YFLogxK
U2 - 10.1128/JCM.00144-07
DO - 10.1128/JCM.00144-07
M3 - Article
C2 - 17507516
AN - SCOPUS:34547637010
SN - 0095-1137
VL - 45
SP - 2309
EP - 2311
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 7
ER -